Ljoki A, Aslam T, Friis T, Ohm R, Houen G
Int J Mol Sci. 2022; 23(8).
PMID: 35457095
PMC: 9025250.
DOI: 10.3390/ijms23084277.
McCracken J, Balaji S, Keswani S, Hakim J
Adv Wound Care (New Rochelle). 2020; 10(4):165-173.
PMID: 32602816
PMC: 7906868.
DOI: 10.1089/wound.2020.1198.
Ghiselli G
Medicines (Basel). 2019; 6(3).
PMID: 31362364
PMC: 6789896.
DOI: 10.3390/medicines6030080.
Ling L, Tan S, Goh T, Cheung E, Nurcombe V, van Wijnen A
Mol Cancer. 2015; 14:136.
PMID: 26201468
PMC: 4511971.
DOI: 10.1186/s12943-015-0391-4.
Palmer G, Tiran Z, Zhou Z, Capozzi M, Park W, Coletta C
Br J Pharmacol. 2011; 165(6):1891-1903.
PMID: 21943108
PMC: 3372838.
DOI: 10.1111/j.1476-5381.2011.01677.x.
Intravital microscopic characterization of suramin effects in an orthotopic immunocompetent rat model of pancreatic cancer.
Hotz B, Buhr H, Hotz H
J Gastrointest Surg. 2008; 12(5):900-6.
PMID: 18320288
DOI: 10.1007/s11605-008-0507-x.
The effect of suramin on the resorption of bovine nasal cartilage.
Lewis C, Frazer A, Russell R, Bunning R
Inflammopharmacology. 2007; 7(4):387-400.
PMID: 17657441
DOI: 10.1007/s10787-999-0032-x.
Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer.
Bhargava S, Hotz B, Hines O, Reber H, Buhr H, Hotz H
J Gastrointest Surg. 2007; 11(2):171-8.
PMID: 17390169
DOI: 10.1007/s11605-006-0081-z.
Local anti-angiogenic brain tumor therapies.
Sipos E, Brem H
J Neurooncol. 2001; 50(1-2):181-8.
PMID: 11245278
DOI: 10.1023/a:1006482120049.
Multi-agent cytostatic treatment of 'low-grade' gliomas.
Linskey M
Curr Oncol Rep. 2000; 2(5):454-62.
PMID: 11122878
DOI: 10.1007/s11912-000-0066-0.
Antiangiogenic therapy in brain tumor models.
Bernsen H, van der Kogel A
J Neurooncol. 2000; 45(3):247-55.
PMID: 10845396
DOI: 10.1023/a:1006395802727.
Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.
Bernsen H, Rijken P, Peters J, BAKKER J, Boerman R, Wesseling P
J Neurooncol. 2000; 44(2):129-36.
PMID: 10619496
DOI: 10.1023/a:1006363215260.
[Pathophysiologic significance of growth factors and new therapeutic concepts in cardiovascular disease].
Rosenkranz S, Bohm M, Kazlauskas A
Med Klin (Munich). 1999; 94(9):496-504.
PMID: 10544612
DOI: 10.1007/BF03044941.
Angiogenesis: possibilities for therapeutic interventions.
Wynendaele W, Van Oosterom A, Pawinski A, de Bruijn E, Maes R
Pharm World Sci. 1999; 20(6):225-35.
PMID: 9972522
DOI: 10.1023/a:1008600603059.
Platelet-derived growth factor in human brain tumors.
Kirsch M, Wilson J, Black P
J Neurooncol. 1998; 35(3):289-301.
PMID: 9440026
DOI: 10.1023/a:1005872718547.
An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
Gradishar W
Invest New Drugs. 1997; 15(1):49-59.
PMID: 9195289
DOI: 10.1023/a:1005770612294.
Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.
Miao H, Ornitz D, Aingorn E, Ben-Sasson S, Vlodavsky I
J Clin Invest. 1997; 99(7):1565-75.
PMID: 9120000
PMC: 507976.
DOI: 10.1172/JCI119319.
Evaluation of angiogenic inhibitors with an in vivo quantitative angiogenesis method using agarose microencapsulation and mouse hemoglobin enzyme-linked immunosorbent assay.
Okada N, Fushimi M, Nagata Y, Fukunaga T, Tsutsumi Y, Nakagawa S
Jpn J Cancer Res. 1996; 87(9):952-7.
PMID: 8878458
PMC: 5921206.
DOI: 10.1111/j.1349-7006.1996.tb02125.x.
Antitumor activity of FCE 26644 a new growth-factor complexing molecule.
Sola F, Farao M, Pesenti E, Marsiglio A, Mongelli N, Grandi M
Cancer Chemother Pharmacol. 1995; 36(3):217-22.
PMID: 7781141
DOI: 10.1007/BF00685849.
Suramin inhibits glioma cell proliferation in vitro and in the brain.
Takano S, Gately S, Engelhard H, Tsanaclis A, Brem S
J Neurooncol. 1994; 21(3):189-201.
PMID: 7699415
DOI: 10.1007/BF01063768.